Login to Your Account



BIND, Amgen Ink $180.5M Nanomedicine Partnership

By Catherine Shaffer
Staff Writer

Wednesday, January 9, 2013
BIND Biosciences Inc., of Cambridge, Mass., signed a deal with Amgen Inc., of Thousand Oaks, Calif., worth up to $180.5 million. to collaborate on development of a nanotechnology-based therapeutic for solid tumors.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription